Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in transfusion-dependent low or Intermediate-1 risk MDS refractory to ESA
2015-002874-19Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of imetelstat in myelodysplastic syndrome (MDS), sponsored by Janssen Pharmaceutical. Primary endpoint: Red blood cell transfusion independence over any consecutive 8-week period. Started Sep 2015; status: active.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2015-002874-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002874-19.